Search
Chondrus crispus
go.drugbank.com/drugs/DB14367InvestigationalChondrus crispus is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Agrostis gigantea top
go.drugbank.com/drugs/DB14757ApprovedWithdrawnAgrostis gigantea top is mainly used in allergenic testing.
HMI-103
go.drugbank.com/drugs/DB17684InvestigationalHMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.
RCT1100
go.drugbank.com/drugs/DB18830InvestigationalRCT1100 is an investigational mRNA-based therapeutic that aims to treat primary ciliary dyskinesia caused by pathogenic mutations in DNAI1.[L50788]
Fludarabine
go.drugbank.com/drugs/DB01073ApprovedInvestigationalFludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
Bifunctional epoxide hydrolase 2
go.drugbank.com/drugs/DB15139InvestigationalBifunctional epoxide hydrolase 2 is under investigation in clinical trial NCT00654966 (Evaluation of the Effects of Urotensin-II and Soluble Epoxide Hydrolase Inhibitors on Skin Microvessel Tone in Patients … With Heart Failure, and in Healthy Volunteers).
D-threo-neopterin
go.drugbank.com/drugs/DB02385Experimental(From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin. … A pteridine derivative present in body fluids; elevated levels result from immune system activation, malignant disease, allograft rejection, and viral infections.
Synonyms: D-monapterin, D-threo-neopterinSB-509
go.drugbank.com/drugs/DB05579InvestigationalSB-509 is under investigation in multiple clinical trials for the treatment of Diabetic Neuropathy.
Tesaglitazar
go.drugbank.com/drugs/DB06536InvestigationalTesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. … Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.
Vapreotide
go.drugbank.com/drugs/DB04894InvestigationalVapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.